Anzeige
Mehr »
Dienstag, 14.10.2025 - Börsentäglich über 12.000 News
Defence-Boom 2025: Jetzt im Fokus der NATO-Partner - weitere Kursfantasie nach dieser Einladung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QQGU | ISIN: CA4236943060 | Ticker-Symbol: 2VF0
Stuttgart
14.10.25 | 07:57
0,064 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
HEMOSTEMIX INC Chart 1 Jahr
5-Tage-Chart
HEMOSTEMIX INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0530,07423:00
0,0600,06621:53

Aktuelle News zur HEMOSTEMIX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrHemostemix Inc (2): Hemostemix applies for vascular dementia study approval4
DoHemostemix Inc.: Hemostemix Files for Ethics Approval of its Study of Vascular Dementia280Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has filed its Institutional Review...
► Artikel lesen
MiHemostemix Inc (2): Hemostemix receives $330,000 lead order for placement2
07.10.Hemostemix Inc.: Hemostemix's Insider Lead Order of $330,000 Private Placement272Calgary, Alberta--(Newsfile Corp. - October 7, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce a lead order of $330,000 for a non brokered...
► Artikel lesen
24.09.Hemostemix Inc (2): Hemostemix files FDA trial for ACP-01 stem therapy2
HEMOSTEMIX Aktie jetzt für 0€ handeln
23.09.Hemostemix Inc.: Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell) Across Multiple Ischemic and Vascular Indications Simultaneously327Calgary, Alberta--(Newsfile Corp. - September 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)...
► Artikel lesen
17.09.Hemostemix Inc.: Hemostemix to Present at Life Science Investor Forum164Calgary, Alberta--(Newsfile Corp. - September 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)...
► Artikel lesen
16.09.Hemostemix Inc.: Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina330Calgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)...
► Artikel lesen
12.09.Hemostemix Inc (2): Hemostemix two million shares for debt2
11.09.Hemostemix Inc (2): Hemostemix to issue two million shares for debt2
10.09.Hemostemix Inc.: Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share430Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous (patient's own) stem cell therapy company offering...
► Artikel lesen
10.09.Hemostemix Inc (2): Hemostemix arranges $280,594 private placement2
09.09.Hemostemix Inc (2): Hemostemix launches corporate website1
09.09.Hemostemix announces $280K non-brokered private placement3
09.09.Hemostemix Inc.: Hemostemix Announces Private Placement315Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)...
► Artikel lesen
09.09.Hemostemix Inc.: Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients319Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)...
► Artikel lesen
05.09.Hemostemix Inc (2): Hemostemix rolls out VesCell.Health in Florida2
04.09.Hemostemix Inc.: Hemostemix's VesCell.Health Launched in Florida346Calgary, Alberta--(Newsfile Corp. - September 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)...
► Artikel lesen
04.09.Hemostemix Inc (2): Hemostemix cheers 17 "years of line gained" by Lindeman16
03.09.Hemostemix Inc.: Howie's 17+ Years After VesCell: Following Hemostemix's Heart Patients341Calgary, Alberta--(Newsfile Corp. - September 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)...
► Artikel lesen
Weiter >>
88 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1